Naphthyl Group Patents (Class 562/490)
-
Patent number: 5919970Abstract: Compounds of the formulaY.sub.3 (R.sub.4)--X--Y.sub.1 (R.sub.1 R.sub.2)--Z--Y.sub.2 (R.sub.2)--A--Bwhere the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid inverse agonist type biological activity.Type: GrantFiled: April 24, 1997Date of Patent: July 6, 1999Assignee: Allergan Sales, Inc.Inventors: Tae K. Song, Min Teng, Roshantha A. Chandraratna
-
Patent number: 5917082Abstract: Enantiomerically substantially pure compounds of the formula ##STR1## where R is H or lower alkyl of 1 to 6 carbons, or pharmaceutically acceptable salts thereof have retinoid-like biological activity. The enantimerically pure or substantially pure compound of the above formula where R is H, or a pharmaceutically acceptable salt thereof, is highly specific agonist of RXR retinoid receptors in preference over RAR receptors.Type: GrantFiled: August 20, 1997Date of Patent: June 29, 1999Assignee: Allergan Sales, Inc.Inventors: Vidyasagar Vuligonda, Roshantha A. Chandraratna
-
Patent number: 5866604Abstract: Compounds of formula (I) wherein R, R.sub.1, R.sub.2, R.sub.3, R.sub.4, m and n have the meanings reported in the description, processes for their preparation and pharmaceutical compositions which contain them as active ingredients are described. The compounds of formula (I) are endowed with a mixed ACE-inhibitory and NEP-inhibitory activity and are useful in the treatment of cardiovascular diseases.Type: GrantFiled: December 24, 1996Date of Patent: February 2, 1999Assignee: Zambon Group S.p.A.Inventors: Franco Pellacini, Stefano Romagnano, Gabriele Norcini, Francesco Santangelo
-
Patent number: 5837725Abstract: Bridged bicyclic aromatic compounds are provided having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as defined herein. The novel compounds are useful for modulating gene expression of retinoic acid receptors, vitamin D receptors and thyroid receptors. Pharmaceutical compositions and methods for modulating gene expression are provided as well.Type: GrantFiled: May 24, 1995Date of Patent: November 17, 1998Assignees: SRI International, La Jolla Cancer Research FoundationInventors: Marcia I. Dawson, James F. Cameron, Peter D. Hobbs, Ling Jong, Magnus Pfahl, Xiao-kun Zhang, Jurgen M. Lehmann
-
Patent number: 5834468Abstract: This invention relates to substituted and unsubstituted ???(aryl- and heteroaryl-) alkyl-, alkyloxy-, alkylthio-, oxo-, thio-, and alkylamino!- heteroaryl and aryl!- alkylamino-, aminoalkyl-, alkyloxy-, and alkylthio!- aryl and heteroaryl compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof, which are useful as antagonists of the pain enhancing effects of E-type prostaglandins, to processes for the preparation of such compounds, to pharmaceutical compositions comprising such compounds, and to methods for treating pain comprising the administration of such compounds.Type: GrantFiled: July 2, 1996Date of Patent: November 10, 1998Assignee: Zeneca LimitedInventors: Gloria Anne Breault, John Oldfield, Howard Tucker, Peter Warner
-
Patent number: 5808124Abstract: Compounds of the formula ##STR1## where the symbols have the meaning described in the application, have retinoid-like or retinoid antagonist-like biological activity.Type: GrantFiled: June 21, 1996Date of Patent: September 15, 1998Assignee: AllerganInventors: Richard L. Beard, Min Teng, Alan T. Johnson, Vidyasagar Vuligonda, Roshantha A. Chandraratna
-
Patent number: 5801253Abstract: Compounds of formula (I) wherein R.sup.1 -R.sup.7, R.sup.10, X and the dotted bond have the meaning given in the specification, bind selectively to retinoid RXR receptors and are useful as antiproliferative agents for dermatological and oncological indications.Type: GrantFiled: January 21, 1997Date of Patent: September 1, 1998Assignee: Hoffmann-La Roche Inc.Inventors: Michael Klaus, Allen John Lovey, Peter Mohr, Michael Rosenberger
-
Patent number: 5780676Abstract: Compounds, compositions, and methods for modulating processes mediated by Retinoid X Receptors using retinoid-like compounds which have activity selective for members of the subclass of Retinoid X Receptors (RXRs), in preference to members of the subclass of Retinoic Acid Receptors (RARs). Examples of such compounds are bicyclic benzyl, pyridinyl, thiophene, furanyl, pyrrole, and poiyenoic acid derivatives including carbocyclic polyenoic acids. The disclosed methods employ compounds for modulating processes selectively mediated by Retinoid X Receptors.Type: GrantFiled: June 7, 1995Date of Patent: July 14, 1998Assignee: Ligand Pharmaceuticals IncorporatedInventors: Marcus F. Boehm, Richard A. Heyman, Lin Zhi, Chan Kou Hwang, Steve White, Alex Nadzan
-
Patent number: 5773651Abstract: Process for the preparation of fluorine-containing compounds by reduction in a container provided with a stirrer, the stirrer being constructed entirely or partly of a carbon material.Type: GrantFiled: November 27, 1996Date of Patent: June 30, 1998Assignee: Hoechst AktiengesellschaftInventors: Ralf Pfirmann, Friedrich Seitz
-
Patent number: 5736480Abstract: Supported phase catalysts in which the support phase, is non-aqueous and highly polar, such as a primary alcohol, and most preferably ethylene glycol, are. disclosed. An organometallic compound, preferably a metal complex of chiral sulfonated 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl is dissolved in the ethylene glycol. Such supported phase catalysts are useful for asymmetric synthesis of optically active compounds, such as the preparation of dehydronaproxen.Type: GrantFiled: January 12, 1995Date of Patent: April 7, 1998Assignee: California Institute of TechnologyInventors: Mark E. Davis, Kam To Wan
-
Patent number: 5710194Abstract: The invention provides polymerizable dental, compounds, compositions, including the compounds and products for mixing the compositions and methods of using the compositions. Aryl acid compounds are provided in accordance with the invention. The compositions include at least one polymerizable aryl acid compound, an effective amount of a polymerization initiator, and at least 10 percent by weight of ceramic, metal and/or metal oxide filler particles having a particle size less than 500 microns. The dental products of the invention include a polymerizable composition in an enclosure having at least two chambers separated by a wall adapted to be ruptured prior to or during mixing of the composition. Compositions of the invention are preferred for use in these enclosures. Core build up material including a polymerizable acid containing compound is used to support dental crowns and adhere them to teeth in accordance with the invention.Type: GrantFiled: February 15, 1996Date of Patent: January 20, 1998Assignee: Dentsply Research & Development Corp.Inventors: Paul D. Hammesfahr, Kewang Lu, Paul A. Silver
-
Patent number: 5705167Abstract: Novel pharmaceutically/cosmetically-active aromatic polyenic compounds have the structural formula (I): ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular, bone and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.Type: GrantFiled: April 26, 1995Date of Patent: January 6, 1998Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Jean-Michel Bernardon, Philippe Nedoncelle
-
Patent number: 5696162Abstract: Compounds of Formula 1 ##STR1## wherein m is 1-4; R.sub.1 -R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R.sub.5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R.sub.6 is hydrogen, lower alkyl, Cl, Br, I, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH.sub.2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 OR NR.sub.11 --COR.sub.11 ; R.sub.20 is independently hydrogen or lower alkyl; Y is an aromatic group such as phenyl or naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.Type: GrantFiled: June 2, 1995Date of Patent: December 9, 1997Assignee: AllerganInventor: Roshantha A. Chandraratna
-
Patent number: 5686586Abstract: A polycyclic aromatic compound having the formula ##STR1## and its salts have useful therapeutic and cosmetic action particularly in psoriasis.In the formula, X represents --CH.dbd.CH--, O or S,R.sub.1 represents hydrogen, branched alkyl having 3-15 carbon atoms, alkoxy having 1-6 carbon atoms or 1-adamantyl, R.sub.2 represents hydroxy, hydrogen, linear or branched alkyl having 1-15 carbon atoms or alkoxy having 1-6 carbon atoms, with the proviso that R.sub.1 and R.sub.2 are not simultaneously hydrogen, or R.sub.1 and R.sub.2 together with the adjacent carbon atoms of the naphthalene ring form a 5 or 6 chain ring optionally substituted by at least one lower alkyl radical, or interrupted by an oxygen atom,R.sub.3 represents --CH.sub.2 OH or --COR.sub.4, or --CH.sub.3 when R.sub.1 and R.sub.2 taken together form a 5 or 6 chain ring,R.sub.4 represents --OR.sub.5 or ##STR2## R.sub.Type: GrantFiled: October 4, 1996Date of Patent: November 11, 1997Assignee: Centre International de Recherches Dermatologiques GaldermaInventors: Braham Shroot, Jacques Eustache, Oliver Watts, Jean-Michel Bernardon, Philippe Nedoncelle
-
Patent number: 5684046Abstract: Described herein are Benzopyran and other benzo-fused leukotriene B.sub.4 antagonists have the formula ##STR1## wherein R.sup.1 is a phenyl or substituted phenyl group, and A, n, R.sup.2 and R.sup.3 are as defined herein.Type: GrantFiled: May 3, 1996Date of Patent: November 4, 1997Assignee: Pfizer IncInventor: Kevin Koch
-
Patent number: 5675033Abstract: Compounds of Formula 1 ##STR1## wherein Z is selected from the group consisting of the radicals shown in Formula 2 and in Formula 3, ##STR2## Y is cycloalkyl or cycloalkenyl of 3 to 8 carbons optionally substituted with one or two R.sub.4 groups, or Y is selected from phenyl, pyridyl, thienyl, furyl, pyrrolyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl, oxazolyl, and imidazolyl, said groups being optionally substituted with one or two R.sub.4 groups, the divalent Y radical being substituted by the Z and --CR.sub.1 .dbd.CR.sub.1 --CR.sub.1 .dbd.CR.sub.1 groups on adjacent carbons; X is S, O, or NR.sub.5 ; n is 1 or 2; R.sub.1 and R.sub.2 independently are H, lower alkyl or fluoroalkyl; R.sub.3 is hydrogen, lower alkyl, Cl or Br; R.sub.4 is lower alkyl, fluoroalkyl or halogen; R.sub.5 is H or lower alkyl, and B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.Type: GrantFiled: June 6, 1995Date of Patent: October 7, 1997Assignee: AllerganInventors: Vidyasagar Vuligonda, Roshantha A. Chandraratna
-
Patent number: 5648514Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning described in the specification, have retinoid-like biological activity.Type: GrantFiled: December 29, 1994Date of Patent: July 15, 1997Assignee: AllerganInventors: Alan T. Johnson, Min Teng, Vidyasagar Vuligonda, Richard L. Beard, Samuel J. Gillett, Tien T. Duong, Roshantha A. Chandraratna
-
Patent number: 5629321Abstract: The invention relates to a novel compound which is represented by the formula (1) and has an excellent platelet aggregation inhibiting action based on fibrinogen antagonism. The platelet aggregation inhibitor containing the compound of the formula (1) as an effective ingredient are effective for prevention and curing of thrombosis and restenosis or reocclusion after percutaneous transluminal coronary angioplasty or percutaneous transluminal coronary recanalization.Type: GrantFiled: October 18, 1995Date of Patent: May 13, 1997Assignee: Mitsui Toatsu Chemicals, Inc.Inventors: Kunio Okumura, Isao Yokoyama, Toshiyuki Shimazaki, Michihiko Miyamoto, Hiroyuki Yamashita, Kenji Kibayashi, Takanori Yutaka, Kouhei Yazawa
-
Patent number: 5618839Abstract: The present invention relates to a compound of formula I ##STR1## or a nontoxic pharmaceutically acceptable salt, physiologically hydrolyzable ester or solvate thereof, in whichX is --O--CO--, --NH--CO--, --CS--NH--, --CO--O--, --CO--NH--, --COS--, --SCO--, --SCH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --C.tbd.C--, --CH.sub.2 --NH--, --COCH.sub.2 --, --NHCS--, --CH.sub.2 S--, --CH.sub.2 O--, --OCH.sub.2 --, --NHCH.sub.2 -- or --CR.sup.5 .dbd.CR.sup.6 --;R.sup.m and R.sup.k are independently hydrogen, halogen, C.sub.1-6 alkyl, hydroxy, C.sub.1-6 alkyloxy or nitro;n is zero or one;R.sup.4 is --(CH.sub.2).sub.t --Y, C.sub.1-6 alkyl, or C.sub.3-6 cycloalkyl;R.sup.1 is --CO.sub.2 Z, C.sub.1-6 alkyl, CH.sub.2 OH, --CONHR.sup.y, or CHO;R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1-6 alkyl;R.sup.a and R.sup.b are independently hydrogen or C.sub.1-6 alkyl; but when n is one, R.sup.a and R.sup.Type: GrantFiled: May 2, 1996Date of Patent: April 8, 1997Assignee: Bristol-Myers Squibb CompanyInventors: John E. Starrett, Jr., Kuo-Long Yu, Muzammil M. Mansuri, David R. Tortolani, Peter R. Reczek
-
Patent number: 5599967Abstract: Compounds of the formula ##STR1## wherein the symbols have the meaning defined in the specification have retinoid-like biological activity.Type: GrantFiled: December 29, 1994Date of Patent: February 4, 1997Assignee: AllerganInventors: Vidyasagar Vuligonda, Richard L. Beard, Alan T. Johnson, Min Teng, Tae K. Song, Roshantha A. Chandraratna
-
Patent number: 5550296Abstract: A liquid ammonia stream is mixed with a crude oil stream which contains naphthenic acids. Ammonium naphthenates are formed which are then separated from the crude oil with the ammonia. The naphthanates are converted back to acids by addition of acetic acid. Calcium hydroxide is added to form calcium naphthenates and the mixture is pyrolysized which produces ketones.Type: GrantFiled: December 2, 1994Date of Patent: August 27, 1996Assignee: Shell Oil CompanyInventor: Weston W. Haskell
-
Patent number: 5543564Abstract: This invention embodies a process for releasing acidic organic compounds in high yield and good purity from aqueous solutions of their salts which comprises converting the salts by carbon dioxide to their corresponding free acidic organic compounds and metal hydrogen carbonates, removing the acidic organic compounds from the mixture by extraction with an essentially water-insoluble organic solvent, and re-extracting the organic phase with carbon dioxide containing water. Using this process, the acidic organic compounds are completely released from their corresponding salts, i.e., the organic solution is free of salt. The acidic organic compounds released by the claimed process are organic compounds which contain acidic protons which can be replaced by metals. Some examples are carboxylic acids, sulfonic acids, phosphonic acids, phenols, naphthols, and aliphatic alcohols.Type: GrantFiled: January 11, 1995Date of Patent: August 6, 1996Assignee: Hoechst AktiengesellschaftInventors: J urgen Kulpe, Heinz Strutz, Hans-Martin R uffer, Siegbert Rittner
-
Patent number: 5530157Abstract: Novel benzoic acid derivatives have the formula: ##STR1## wherein --X-- represents C.sub.1 to C.sub.6 alkylene, C.sub.2 to C.sub.6 alkenylene or a divalent moiety having the structure --(CH.sub.2).sub.m --Z-- in which m is an integer from 0 to 3 and Z represents --O--, --S-- or --NH--;--Y-- represents a direct bond, C1 to C.sub.6 alkylene, C.sub.2 to C.sub.6 alkenylene or a divalent moiety having the structure --(CH.sub.2).sub.m --Z--(CH.sub.2).sub.n in which m and n are each, independently, an integer from 0 to 3 and --Z-- represents --O--, --S-- or --NH--;R represents a 5- or 6-membered carbocyclic or heterocyclic ring or a carbocyclic or heterocyclic fused ring system containing up to 10 members in the ring, which carbocyclic, heterocyclic or fused ring system may be saturated or unsaturated and may contain up to two substituents selected from lower alkyl, methoxy, halo and trifluoromethyl; andR.sup.1 and R.sup.Type: GrantFiled: February 16, 1995Date of Patent: June 25, 1996Assignee: Scios Nova Inc.Inventors: Richard Mewshaw, Gregory S. Hamilton
-
Patent number: 5523455Abstract: A compound of formula: ##STR1## in which R.sub.y represents a cyano or carboxymethyl group and its salts.Type: GrantFiled: May 16, 1995Date of Patent: June 4, 1996Assignee: SanofiInventors: Bernard Labeeuw, Danielle Gully, Francis Jeanjean, Jean-Charles Molimard, Robert Boigegrain
-
Patent number: 5523457Abstract: This invention relates to a retinoid mpound of formula I ##STR1## in which Y is --CO--NH--, --CR.sup.2 .dbd.CR.sup.3 --, --CO--O--, --O--CO--, --C(.dbd.S)--NH--, --C.tbd.C--, --O--CH.sub.2 --, --CH.sub.2 --O--, or --CH.sub.2 --CH.sub.2 --;A is --(CH.sub.2).sub.t -- or a bond;Q is phenyl optionally substituted with one to three same or different C.sub.1-6 alkyl, C.sub.1-6 alkoxy, halogen, or --CO.sub.2 R.sup.4 ;R.sup.1 is --CO.sub.2 Z, --CONHR.sup.5, C.sub.1-6 alkyl, --CH.sub.2 OH, or --CHO;R.sup.2, R.sup.3, R.sup.4, R.sup.5, and Z are independently hydrogen or C.sub.1-6 alkyl;t is one to six.Type: GrantFiled: June 2, 1995Date of Patent: June 4, 1996Assignee: Bristol-Myers Squibb CompanyInventors: John E. Starrett, Jr., Muzammil M. Mansuri, David R. Tortolani
-
Patent number: 5470999Abstract: Compounds of Formula 1 ##STR1## where R.sub.1 -R.sub.5 are hydrogen, lower alkyl of 1-6 carbons, or halogen; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub.12).sub.2, or CR.sub.7 OR.sub.13 O, where R.sub.7 is an alkyl, cycloalkyl or alkenyl group containing 1 to 5 carbons, R.sub.8 is an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5 to 10 carbons, or R.sub.8 is phenyl or lower alkylphenyl, R.sub.9 and R.sub.10 independently are hydrogen, an alkyl group of 1 to 10 carbons, or a cycloalkyl group of 5-10 carbons, or phenyl or lower alkylphenyl, R.sub.11 is lower alkyl, phenyl or lower alkylphenyl, R.sub.Type: GrantFiled: December 30, 1993Date of Patent: November 28, 1995Assignee: Allergan, Inc.Inventor: Roshantha A. Chandraratna
-
Patent number: 5466861Abstract: Bridged bicyclic aromatic compounds are provided having the structure ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n are as defined herein. The novel compounds are useful for modulating gene expression of retinoic acid receptors, vitamin D receptors and thyroid receptors. Pharmaceutical compositions and methods for modulating gene expression are provided as well.Type: GrantFiled: November 25, 1992Date of Patent: November 14, 1995Assignees: SRI International, La Jolla Cancer Research FoundationInventors: Marcia L. Dawson, James F. Cameron, Peter D. Hobbs, Ling Jong, Magnus Pfahl, Xiao-kun Zhang, Jurgen M. Lehmann
-
Patent number: 5455265Abstract: Process of treatment of mammals, including humans to treat diseases or conditions of the type which are normally treated with retinoid-like compounds is disclosed, with pharmaceutical compositions containing an active compound which is a selective agonist of the RXR retinoid receptor sites in preference to the RAR retinoid receptor sites. A compound is defined to be a selective agonist of the RXR receptor site if the compound is at least approximately ten times more effective as an agonist in the RXR receptor sites than in the RAR receptor sites.Type: GrantFiled: February 11, 1993Date of Patent: October 3, 1995Assignee: Allergan, Inc.Inventor: Roshantha A. S. Chandraratna
-
Patent number: 5403952Abstract: Novel substituted cyclic compounds of Formula I are found to be useful inhibitors of matrix metalloendoproteinase-mediated diseases including osteoarthritis, rheumatoid arthritis, septic arthritis, tumor invasion in certain cancers, periodontal disease, corneal ulceration, proteinuria, dystrophic epidermolysis bullosa, and coronary thrombosis associated with atherosclerotic plaque rupture. The matrix metalloendoproteinases are a family of zinc-containing proteinases including but not limited to stromelysin, collagenase, and gelatinase, that are capable of degrading the major components of articular cartilage and basement membranes. The inhibitors claimed herein may also be useful in preventing the pathological sequelae following a traumatic injury that could lead to a permanent disability. These compounds may also be useful as novel birth control agents by preventing ovulation or implantation.Type: GrantFiled: October 8, 1993Date of Patent: April 4, 1995Assignee: Merck & Co., Inc.Inventors: William Hagmann, Charles G. Caldwell, Paul R. Gooley
-
Patent number: 5399707Abstract: A process is provided whereby S(+)-ibuprofen or R(-)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of one of the enantiomers in the ibuprofen enantiomeric mixture. Upon precipitation of one ibuprofen enantiomer from the mixture, the overall precipitate and reaction mixture can be held for a sufficient period of time at a second temperature to allow the first precipitate to redissolve into the reaction mixture and the other ibuprofen enantiomer to precipitate out of the mixture in the salt form. Optically active ibuprofen is racemized by being heated at 100.degree. C. to 300.degree. C. in the substantial absence of other materials.Type: GrantFiled: June 10, 1994Date of Patent: March 21, 1995Assignee: Hoechst Celanese CorporationInventors: Apurba Bhattacharya, John R. Fritch, Carl D. Murphy, Larry D. Zeagler, Carina A. McAdams
-
Patent number: 5393924Abstract: Acylamides or amine acylate salts of arylalkanolamines are prepared by reacting an arylisonitrosoalkanone with hydrogen and a carboxylic acid, carboxylic acid anhydride or carboxylic acid ester or mixture thereof in the presence of a transition metal catalyst; optionally the product is converted to the corresponding arylalkanolamine hydrochloride salt by reaction of the acylamide or amine acylate salt of the arylalkanolamine with hydrogen chloride in a C.sub.1 -C.sub.3 alkyl alcohol.Type: GrantFiled: April 29, 1994Date of Patent: February 28, 1995Assignee: Hoechst Celanese CorporationInventors: Ahmed M. Tafesh, Olan S. Fruchey, Charles B. Hilton
-
Patent number: 5391819Abstract: Disclosed herein is a process of making chiral 2-aryl-1,4-butanediamine derivatives useful as neurokinin-A antagonists of Formula 7 ##STR1##Type: GrantFiled: September 30, 1992Date of Patent: February 21, 1995Assignee: Merck & Co., Inc.Inventors: Paul E. Finke, Jeffrey J. Hale, Malcolm Maccoss, Sander G. Mills
-
Patent number: 5380867Abstract: A process is provided whereby S(+)-ibuprofen or R(-)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of one of the enantiomers in the ibuprofen enantiomeric mixture. Upon precipitation of one ibuprofen enantiomer from the mixture, the overall precipitate and reaction mixture can be held for a sufficient period of time at a second temperature to allow the first precipitate to redissolve into the reaction mixture and the other ibuprofen enantiomer to precipitate out of the mixture in the salt form. Optically active ibuprofen is racemized by being heated at 100.degree. C. to 300.degree. C. in the substantial absence of other materials.Type: GrantFiled: October 19, 1993Date of Patent: January 10, 1995Assignee: Hoechst Celanese CorporationInventors: Apurba Bhattacharya, John R. Fritch, Carl D. Murphy, Larry D. Zeagler, Carina A. McAdams
-
Patent number: 5359122Abstract: The preparation of 3-arylacrylic acids and their derivatives I ##STR1## where Ar is aryl which can additionally have substituents which do not react with ketene and are stable under the conditions of the reaction described below, andR.sup.1 is hydrogen, an alkali metal, an alkaline earth metal, ammonium or C.sub.1 -C.sub.20 -alkyl,comprises a first stage in which a dialkyl acetal of an aromatic aldehyde of the formula II ##STR2## where R.sup.2 is C.sub.1 -C.sub.4 -alkyl, is reacted with ketene of the formula CH.sub.2 .dbd.C.dbd.O in the presence of catalytic amounts of a protic or Lewis acid to give a 3-arylpropionic acid derivative of the formula III ##STR3## and a second stage in which this intermediate III is reacted in the presence of acid or base and, in the case where R.sup.1 is C.sub.1 -C.sub.20 -alkyl, additionally with a C.sub.1 -C.sub.20 -alkanol to give the final product I.Type: GrantFiled: February 8, 1994Date of Patent: October 25, 1994Assignee: BASF AktiengesellschaftInventors: Michael Huellmann, Josef Gnad, Rainer Becker
-
Patent number: 5344959Abstract: Compounds of the formula ##STR1## wherein m is 1-4; R.sub.1 -R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R.sub.5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R.sub.6 is hydrogen, lower alkyl, Cl, Br, I, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 OR NR.sub.11 --COR.sub.11 ; R.sub.20 is independently hydrogen or lower alkyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.11, CH.sub.2 OCOR.sub.11, CHO, CH(OR.sub.12).sub.2, CHOR.sub.13 O, --COR.sub.7, CR.sub.7 (OR.sub.12).sub.2, or CR.sub.7 OR.sub.13 O, where R.sub.Type: GrantFiled: May 18, 1993Date of Patent: September 6, 1994Assignee: Allergan, Inc.Inventor: Roshantha A. Chandraratna
-
Patent number: 5344843Abstract: The invention relates to compounds of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.2 ' X, Y, Z, A, B, Q and n are as described herein. Their pharmaceutically acceptable salts, and when appropriate, enantiomers, racemates, diastereomers or mixtures thereof or geometric isomer or mixtures thereof, and pharmaceutically acceptable salts thereof. The compounds of formula I inhibit enzyme carnitine acyltransferase 1 (CAT-1) and are therefore useful in the prevention of injury to ischemic tissue, and can limit infarct size, improve cardiac function and prevent arrhythmias during and following a myocardial infarction.Type: GrantFiled: March 13, 1992Date of Patent: September 6, 1994Assignee: Hoffman-La Roche Inc.Inventors: Robert W. Guthrie, John G. Mullin, Jr., David F. Kachensky, Richard W. Kierstead, Jefferson W. Tilley, Guy P. Heathers, Alan J. Higgins, Ronald A. LeMahieu
-
Patent number: 5344970Abstract: A ruthenium-phosphite complex having the formula ##STR1## wherein a is from 1 to 3; b is 1 or 2; c is from 0 to 3; and R is hydrogen, alkyl, aryl, halo, amino, acetylamino, or sulfo; and X is ##STR2## where R.sub.1, R.sub.2, and R.sub.3 are the same or different and are hydrogen or C.sub.1 to C.sub.6 linear or branched alkyl.This complex can be used to effect the reduction of unsaturated organic compounds or, when comprised of ligands having optical activity, can be used as the catalyst for effecting the asymmetric reduction of unsaturated organic compounds.Type: GrantFiled: December 22, 1993Date of Patent: September 6, 1994Assignee: Albemarle CorporationInventor: Charles H. Kolich
-
Patent number: 5332834Abstract: There is disclosed and claimed a process whereby S(+)-ibuprofen L-lysinate salt is produced by selective precipitation from a mixture containing enantiomers of ibuprofen and L-lysine. The quantity of L-lysine is not more than about a molar equivalent of the quantity of S(+)-ibuprofen in the ibuprofen enantiomeric mixture. The mother liquors after separating the above salt are enriched in R-ibuprofen which is racemized by a novel thermal racemization process and may then be recycled.Type: GrantFiled: December 2, 1992Date of Patent: July 26, 1994Assignee: Hoechst Celanese CorporationInventors: Apurba Bhattacharya, John R. Fritch, Carl D. Murphy, Larry D. Zeagler, Carina Araullo-McAdams
-
Patent number: 5319134Abstract: Disclosed is a process for introducing a carboxyl group to an aromatic carboxylic acid or a derivative thereof, which comprises reacting a starting aromatic carboxylic acid, such as a benzoic acid, a biphenylcarboxylic acid, a naphthalenecarboxylic acid, a diphenylcarboxylic acid, or a derivative thereof, with a carbon tetrahalide in the presence of a cyclodextrin and an alkali metal hydroxide, thereby introducing a carboxyl group to the aromatic ring of the starting aromatic carboxylic acid or the derivative thereof in substitution for a hydrogen atom bonded thereto. By the process of the present invention, a desired aromatic polycarboxylic acid or a derivative thereof can be easily obtained with high selectivity.Type: GrantFiled: October 26, 1992Date of Patent: June 7, 1994Assignee: Hidefumi HiraiInventors: Hidefumi Hirai, Rikinori Terakado, Hisashi Mihori, Tsutomu Nakamura, Kazuhiro Saito
-
Patent number: 5318994Abstract: Compounds of the formula: ##STR1## in which: A represents ##STR2## R represents linear or branched lower alkyl, R.sub.1 represents hydrogen or linear or branched lower alkyl, andR.sub.2 represents aryl or lower arylalkyl or aryl or lower arylalkyl substituted by lower alkyl, lower alkoxy, trifluoromethyl, or halogen, aryl means phenyl or naphthyl, as well as optical isomers, epimers and diastereoisomers and addition salts thereof with a pharmaceutically-acceptable acid, lower alkyl and lower alkoxy having 1 to 6 carbon atoms inclusive, andmedicaments containing the same which are useful for the treatment of disorders of the melatoninergic system.Type: GrantFiled: November 3, 1992Date of Patent: June 7, 1994Assignee: Adir et CompagnieInventors: Jean Andrieux, Raymond Houssin, Said Yous, Beatrice Guardiola, Daniel Lesieur
-
Patent number: 5306833Abstract: Process for obtaining an arylacetic acid of general formula (I):Ar--CHR--COOH (I)in which R=H, C.sub.1 -C.sub.4 alk, Ar=2-thienyl, 3-thienyl, 1-naphthyl, 2-naphthyl, 1-(2-methoxy naphthyl), 3,4-methylenedioxy phenyl or phenyl of general formula (II): ##STR1## in which R.sub.1 =H, OH or C.sub.1 -C.sub.4 alkoxy, R.sub.2 =H, C.sub.1 -C.sub.4 alk, C.sub.1 -C.sub.4 alkoxy or OH, as well as their alkali metal salts, by reaction in a solvent of the corresponding arylglycolic acid of general formula (III):Ar-CR(OH)--COOH (III)or one of its alkali metal salts with a hydrogen donor agent chosen from the group constituted by: formic acid, or one of its alkali metal salts, phosphonic acid, phosphinic acid, or one of their alkali metal salts, in the presence of a hydrogen transfer catalyst, which if desired is isolated or salified, and use for the preparation of certain acids of formula (I).Type: GrantFiled: February 3, 1993Date of Patent: April 26, 1994Assignee: Societe Francaise HoechstInventors: Jean-Claude Vallejos, Yani Christidis
-
Patent number: 5274186Abstract: Compounds of formula ##STR1## (wherein Ar, R, R.sub.1 and X have the meaning reported in the description) are useful intermediates for the preparation of a variety of organic compounds, also optically active, like alpha-haloketones, alpha-hydroxyketones or ketals, alpha-arylalkanoic acids.Type: GrantFiled: January 19, 1989Date of Patent: December 28, 1993Assignee: Zambon S.p.A.Inventors: Claudio Giordano, Graziano Castaldi
-
Patent number: 5266723Abstract: A chemical process is disclosed for the preparation of a pharmaceutically active compound in an enantiomeric form either (R) or (S) of the structure ##STR1## and a suitable pharmaceutical salt, e.g. alkali or earth metal, D-glucamine or D-ribamine, where R.sub.1 represents an optionally substituted aryl group same as phenyl or naphthyl group, optionally including a heterocyclic ring system, which is optionally substituted, or represents a hetero-aromatic ring system optionally containing in addition to carbon atoms one or more atoms selected from the group consisting of nitrogen and oxygen; the enantiomeric R or S-compounds of (I) are obtained from a suitable ketone (II) by reduction with an LiAlH.sub.4.sup.Type: GrantFiled: February 27, 1990Date of Patent: November 30, 1993Assignee: Medice, Ltd., Chem.-Pharm. Fabrik Putter GmbH & Co. KGInventors: Samir B. Hanna, Bernd Schneider, Henrich H. Paradies
-
Patent number: 5260428Abstract: A process for the detection of substances with hydrolase activity in a sample by mixing the sample with a hydrolase substrate and an oxidising agent, and the evaluating the resultant colour intensity, wherein, as hydrolase substrate, there is used at least one compound of the formula ##STR1## in which R.sup.1 is hydrogen or an alkoxy radical,R.sup.2 is hydrogen or halogen, an amino group or an alkoxy or aralkoxy radical,R.sup.3, R.sup.4, R.sup.5, R.sup.6, which can be the same or different, are hydrogen, halogen, carboxyl, a carbamoyl group, sulpho, an amino groups alkyl, an alkoxy radical, aralkoxy, alkylcarbonyl or alkoxycarbonyl, andX is a glycosyl, phosphate or acyl residue. Optionally R.sup.2 and R.sup.3, R.sup.3 and R.sup.4, R.sup.4 and R.sup.5, and R.sup.5 and R.sup.6 can be joined to form a ring system. At least one of R.sup.1 and R.sup.2 must be hydrogen and at least one of R.sup.1, R.sup.2 and R.sup.3 must not be hydrogen. Compounds in which X is .beta.-galactosyl are new.Type: GrantFiled: January 29, 1993Date of Patent: November 9, 1993Assignee: Boehringer Mannheim GmbHInventors: Rupert Herrmann, Hans-Joachim Guder, Werner Guthlein, Manfred Kuhr, Johann Berger, Harvey Buck
-
Patent number: 5258547Abstract: A process for preparing halogenated compounds of formula RCY(Z)CH.sub.2 CH(X)C(CH.sub.3)CH.sub.2 COR.sup.1 where X, Y and Z are halo, R is alkyl, halo, haloalkyl or aryl, and R.sup.1 is hydroxy, halo, alkoxy, alkyl or haloalkyl, or the residue of a pyrethroidal alcohol, in which a compound of formula CH.sub.2 =CHC(CH.sub.3).sub.2 COR.sup.1 is reacted with a sulphonyl halide of formula RCY(Z)SO.sub.2 X. The process avoids the use of volatile halocarbons in the production of valuable intermediates for insecticides.Type: GrantFiled: January 9, 1992Date of Patent: November 2, 1993Assignee: Imperial Chemical Industries plcInventor: Gary N. Sheldrake
-
Patent number: 5254728Abstract: Complexes containing S(+)-ibuprofen, method for the production of these complexes and pharmaceutical preparations containing these complexes are described.Type: GrantFiled: November 15, 1991Date of Patent: October 19, 1993Assignee: Medice Chem.-pharm. Fabrik Putter GmbH & Co. KGInventor: Henrich H. Paradies
-
Patent number: 5248815Abstract: The present invention relates to a stereospecific chemical synthesis of optically pure enantiomers of 2-aryl-alkanoic acids, especially those of the biologically active (S)-aryl-propionic acids, in good chemical yields, useful for preparing large quantities thereof, and having a high optical purity.Type: GrantFiled: December 27, 1991Date of Patent: September 28, 1993Inventor: Henrich H. Paradies
-
Patent number: 5237092Abstract: A process for efficiently producing aryl formate and aromatic carboxylic acid from aldehyde, which comprises oxidizing an aromatic aldehyde with an oxygen-containing gas in the presence of a volatile solvent up to a reaction ratio of 40 to 70 mol % to convert the aromatic aldehyde to a peracid, adding a stabilizer, and allowing the remaining aromatic aldehyde and the aromatic peracid to react while the volatile solvent is distilled off.Type: GrantFiled: June 16, 1992Date of Patent: August 17, 1993Assignee: Mitsubishi Gas Chemical Company, Inc.Inventors: Toru Tanaka, Kazuo Tanaka, Teruo Aratake
-
Patent number: 5223640Abstract: This invention provides a process to prepare optically active .alpha.-aryl propionic acids without the need for resolving a racemic mixture. In one embodiment of the process, an acetophenone is sequentially converted to a 1-alkyne, then to an .alpha.-aryl .beta.-silylated acrolein, and then to an acrylic acid, which is then asymmetrically hydrogenated to an optically active .alpha.-aryl propionic acid.Type: GrantFiled: December 23, 1992Date of Patent: June 29, 1993Assignee: Hoechst Celanese CorporationInventors: Ahmed M. Tafesh, Sambasivarao Kotha, Kenneth G. Davenport
-
Patent number: RE34805Abstract: A benzonaphthalene compound has the formula ##STR1## wherein R.sub.1 represents ##STR2## or (ii) --CH.sub.2 OH; R.sub.6 represents ##STR3## or OR.sub.7 wherein R.sub.7 represents hydrogen, alkyl having 1-20 carbon atoms, monohydroxyalkyl or polyhydroxyalkyl, r' or r" represent hydrogen, lower alkyl, mono or polyhydroxyalkyl, aryl or a residue of an amino acid or a sugar, or together form a heterocycle; R.sub.2 represents hydrogen, alkyl having 1-15 carbon atoms, alkoxy having 1-4 carbon atoms or a cycloaliphatic radical; R.sub.3 represents hydrogen, hydroxy, alkyl having 1-4 carbon atoms, alkoxy having 1-10 carbon atoms, a cycloaliphatic radical, a thiocycloaliphatic radical or --O--Si(CH.sub.3).sub.2 --R.sub.8 wherein R.sub.8 represents lower alkyl; and R.sub.4 and R.sub.5 represent hydrogen, lower alkyl, hydroxy or lower acyloxy.This compound is useful in the topical and systemic treatment of dermatologic diseases and in the treatment of the degeneration of conjunctive tissues.Type: GrantFiled: July 10, 1992Date of Patent: December 6, 1994Assignee: Centre International de Recherches Dermatologiques (CIRD)Inventors: Braham Shroot, Jacques Eustache, Jean-Michel Bernardon